Joël Fokom Domgue

Dr. Joël Fokom Domgue


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2015 in BMJ
Verified
Journal Article
Open access
JDJoël Fokom Domgue
Joël Fokom Domgue
CCChristophe Combescure
Christophe Combescure
VFVictoire Fokom-Defo
Victoire Fokom-Defo
PTPierre Marie Tebeu
Pierre Marie Tebeu
PVPierre Vassilakos
Pierre Vassilakos
PPPatrick Petignat
Patrick Petignat
F1000Prime Recommended Article: Performance of alternative strategies for primary cervical cancer screening in sub-Saharan Africa: systematic review and meta-analysis of diagnostic test accuracy studies.

7 March 2019 in The Journal of Clinical Hypertension
Verified
Journal Article
Open access
PDF file
JNJoan Jacques Noubiap
Joan Jacques Noubiap
JBJean Joel Bigna
Jean Joel Bigna
UNUlrich Flore Nyaga
Ulrich Flore Nyaga
AJAhmadou M. Jingi
Ahmadou M. Jingi
AKArnaud D. Kaze
Arnaud D. Kaze
JDJoël Fokom Domgue
Joël Fokom Domgue
Hypertensive disorders of pregnancy (HDP) are a major contributor to maternal and perinatal morbidity and mortality, especially in resource‐limited settings. Little is known about the magnitude of HDP in Africa. We conducted the first systematic review and meta‐analysis to summarize available data on the prevalence of HDP in Africa. We did a comprehensive literature search to identify review paper published from January 1, 1996, to September 30, 2017, and searched the reference list of retrieved review paper. We used a random‐effects model to estimate the overall and type‐specific prevalence of HDP in Africa. We included 82 studies published between 1997 and 2017 reporting data on a pooled sample of 854 304 women during pregnancy or puerperium. Most studies were hospital‐based, conducted in urban settings across 24 countries. In this population, the overall prevalence of HDP was 100.4‰ (95% CI: 81.4‐121.2). The prevalence was 49.8‰ (95% CI: 32.3‐70.7) for gestational hypertension, 14.7‰ (95% CI: 11.6‐18.2) for chronic hypertension, 9.2‰ (95% CI: 4.2‐16.0) for superimposed preeclampsia, 44.0‰ (95% CI: 36.7‐52.0) for preeclampsia, 22.1‰ (95% CI: 14.8‐30.8) for severe preeclampsia, 14.7‰ (95% CI: 8.1‐23.2) for eclampsia and 2.2‰ (95% CI: 1.2‐3.4) for HELLP syndrome. Prevalence of HDP was significantly higher in Central and Western Africa; there was a consistent tendency of increasing HDP prevalence with income at the country level. In conclusion, the burden of HDP in Africa is high, with about one in 10 pregnancies affected. The higher rate of severe forms of HDP that are associated with significant maternal and perinatal mortality is a major concern in the region.

2 May 2015 in BMC Public Health
Verified
Journal Article
Open access
PDF file
JNJoan Jacques Noubiap
Joan Jacques Noubiap
JNJobert Richie N Nansseu
Jobert Richie N Nansseu
SNShalom Tchokfe Ndoula
Shalom Tchokfe Ndoula
JBJean Joel R Bigna
Jean Joel R Bigna
AJAhmadou M Jingi
Ahmadou M Jingi
JDJoël Fokom Domgue
Joël Fokom Domgue
Epidemiological data on hepatitis B virus (HBV) infection among pregnant women in Cameroon are very scarce, especially in the rural milieu. The purpose of this study was to determine the prevalence and factors associated with HBV infection, and the infectivity of rural pregnant women in the Far North Region of Cameroon. A cross-sectional study was conducted in three rural health facilities of the Guidiguis health district between December 2013 and March 2014. We consecutively recruited 325 pregnant women attending antenatal consultations. A pretested questionnaire was used to collect socio-demographic data and factors associated with HBV infection. The presence of hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and human immunodeficiency virus (HIV) were determined using commercial test strips. Regression analyses were used to assess correlates of HBV infection. The mean age was 24.4 (SD5.6) years. Most women were married (97.2%) and housewives (96.4%), with less than secondary education level (80%). Only 4 women (1.2%) had been vaccinated against HBV. Thirty-three women (10.2%) were HBsAg-positive, of whom 4 (12.1%) were positive to HBeAg. The prevalence of HIV infection was 2.5% (8/325). Overall, 5 (1.5%) women were co-infected with HIV and HBV. Independent correlates of HBV infection included history of blood transfusion (adjusted odd ratio 12.59, 95% CI 1.46-108.89; p = 0.021) and concurrent infection by HIV (adjusted odd ratio 22.53, 95% CI 4.76-106.71; p < 0.0001). The prevalence of HBV infection among pregnant women in this rural milieu is high. History of blood transfusion and HIV infection are highly associated with HBV infection. The relative low rate of women positive to both HBsAg and HBeAg suggests that perinatal transmission of HBV might not be the prevailing mode of HBV transmission in this area.

24 November 2014 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
JBJérôme Bigoni
Jérôme Bigoni
MGMélissa Gundar
Mélissa Gundar
PTPierre‐Marie Tebeu
Pierre‐Marie Tebeu
ABAdamo Bongoe
Adamo Bongoe
SSSonja Schäfer
Sonja Schäfer
PPPatrick Petignat
Patrick Petignat
Developing countries are interested in using human papillomavirus (HPV) testing as a primary screening test for cervical cancer prevention programs. The low specificity of the HPV assay requires triage testing of HPV‐positive women. The aim of the study is to compare visual inspection with acetic acid (VIA) and cytology as triage testing methods in HPV‐positive women to detect cervical intraepithelial neoplasia or Grade 2 or higher (CIN2+). The study was conducted in two Cameroonian towns (Yaoundé and Edea) and included 846 eligible women aged 25 to 65 years. All participants performed self‐HPV testing. HPV‐positive women (n = 259) were randomly assigned to be tested either by VIA (VIA group) or cytology (cytology group). HPV‐positive women had both cervical biopsy and endocervical curettage to detect biopsy‐confirmed CIN2+. All statistical tests were two‐sided. The prevalence of HPV was 38.5%, and the mean age of HPV‐positive women was 41.5 ± 10.1 years. One hundred ninety‐eight women (97 in the VIA group and 99 in the cytology) were randomly assigned to one of the two testing arms. The sensitivity of VIA was 25.0% (95% CI, 7.1–59.1%), and the sensitivity of cytology was 90.0% (59.6–98.2%). The specificity was 74.2% (95% CI, 64.2–82.1%) for VIA and 85.2% (76.3–91.2%) for cytology. ROC area for cytology was 0.910 against the 0.496 area for VIA. In this trial, VIA was inferior to cytology as a triage test among HPV‐positive women. Further investigations are needed to determine the optimal triage method for HPV‐positive women.

4 October 2014 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
PTPierre‐Marie Tebeu
Pierre‐Marie Tebeu
JDJoël Fokom Domgue
Joël Fokom Domgue
VCVictoria Crofts
Victoria Crofts
EFEmmanuel Flahaut
Emmanuel Flahaut
RCRosa Catarino
Rosa Catarino
PPPatrick Petignat
Patrick Petignat
The World Health Organization recently advocated a two‐stage strategy with human papillomavirus (HPV) testing followed by visual inspection of the cervix with acetic acid (VIA) as a suitable option for cervical cancer screening. However, its accuracy has never been directly assessed in the context of primary screening. To evaluate effectiveness of HPV testing on self‐obtained specimens (self‐HPV) followed by VIA (sequential testing) in a low‐income setting, we recruited 540 women aged between 30 and 65 years in two Cameroonian periurban areas. Eligible women were counseled about cervical cancer and how to perform self‐sampling. HPV positive and a random sample of HPV‐negative women were called back for VIA and biopsy. Disease was defined by interpretation of cervical intraepithelial neoplasia Grade 2 or worse (CIN2+). Performances of VIA, self‐HPV and sequential testing were determined after adjustment for verification bias. HPV prevalence was 27.0%. VIA positivity was 12.9% and disease prevalence was 5%. Sensitivity and specificity of VIA for CIN2+ were 36.4% [95% confidence interval (CI): 15.2–64.6%] and 90.4% (95% CI: 85.4–93.7%), respectively. Sensitivity of self‐HPV [100.0% (95% CI: 79.6–100.0%)] was 66% higher than that of sequential testing [33.3% (95% CI: 15.2–58.3%)]. Meanwhile, specificity of self‐HPV [74.5% (95% CI: 70.6–78.1%)] was 22% lower than that of sequential testing [96.7% (95% CI: 94.8–97.9%)]. A two‐stage screening strategy with self‐HPV followed by VIA improves specificity of cervical cancer screening, but at the cost of an important loss of sensitivity. Ways to improve VIA performance or other tools are needed to increase positive predictive value of HPV testing.

21 October 2019 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
JDJoël Fokom Domgue
Joël Fokom Domgue
BFBeatrice Futuh
Beatrice Futuh
CNCalvin Ngalla
Calvin Ngalla
PKPeter Kakute
Peter Kakute
FMFlorence Manjuh
Florence Manjuh
TWThomas Welty
Thomas Welty